Peter Parker

Peter joined Ampersand in 1988 and served as a General Partner for 18 years. Subsequently, he joined Cequent Pharmaceuticals, an Ampersand portfolio company, as CEO in 2006 before returning to Ampersand as a Senior Advisor in 2011. Peter currently serves on the boards of ATS Labs and Biomedical Structures. Prior to joining Ampersand, Peter spent 14 years at AMAX. He holds an M.S. in Chemical Engineering from Columbia.